Heinz‐Herbert Fiebig
YOU?
Author Swipe
View article: Oleandrin-mediated suppression of MELK induces apoptosis, autophagy, and ferroptosis in human non-small cell lung cancer cells
Oleandrin-mediated suppression of MELK induces apoptosis, autophagy, and ferroptosis in human non-small cell lung cancer cells Open
Oleandrin could potentially have therapeutic effects for NSCLC patients and possibly for other cancer types.
View article: Novel water-soluble and highly efficient dual type I/II next generation inhibitors of FMS-like tyrosine kinase 3 (FLT3)
Novel water-soluble and highly efficient dual type I/II next generation inhibitors of FMS-like tyrosine kinase 3 (FLT3) Open
Mutations of the FMS-like tyrosine kinase (FLT3) occur in acute myeloid leukemia (AML) and are associated with very poor prognosis. Available FLT3 inhibitors are potent but either show a lack of selectivity regarding other tyrosine kinases…
View article: CCDC 2340396: Experimental Crystal Structure Determination
CCDC 2340396: Experimental Crystal Structure Determination Open
An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available …
View article: Data from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
Data from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
BI-847325 is an ATP-competitive inhibitor of MEK/Aurora kinases with the potential to treat a wide range of cancers. In a panel of 294 human tumor cell lines in vitro, BI-847325 was found to be a highly selective inhibitor that was …
View article: FIGURE 4 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
FIGURE 4 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
In vivo antitumor growth efficacy of BI-847325 in 11 solid tumor models grown as subcutaneous xenografts in nude mice. A, Tumor growth curves over time are shown as the relative tumor volumes (%). BI-847325 (either at 80 or 4…
View article: Supplementary Figure S2 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
Supplementary Figure S2 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Supplementary Figure S2 shows the relative body weights of the mice treated with BI-847325 as monotherapy (first in vivo experiment).
View article: TABLE 1 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
TABLE 1 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Human cell line panel (n = 294) and cancer types investigated for BI-847325 efficacy
View article: Supplementary Figure S2 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
Supplementary Figure S2 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Supplementary Figure S2 shows the relative body weights of the mice treated with BI-847325 as monotherapy (first in vivo experiment).
View article: FIGURE 3 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
FIGURE 3 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Association between cell line sensitivities to BI-847325 in vitro and their oncogenic alterations in the RAS/RAF/MAPK pathway. Top: Waterfall plot of BI-847325 Abs IC70 values (y-axis) per cell line (x-axis)…
View article: FIGURE 5 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
FIGURE 5 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
In vivo antitumor growth efficacy of BI-847325 in combination with capecitabine. Combinations (simultaneously or sequentially) were compared with both monotherapies. A, Tumor growth curves are represented as the relative tumo…
View article: FIGURE 4 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
FIGURE 4 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
In vivo antitumor growth efficacy of BI-847325 in 11 solid tumor models grown as subcutaneous xenografts in nude mice. A, Tumor growth curves over time are shown as the relative tumor volumes (%). BI-847325 (either at 80 or 4…
View article: TABLE 1 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
TABLE 1 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Human cell line panel (n = 294) and cancer types investigated for BI-847325 efficacy
View article: FIGURE 3 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
FIGURE 3 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Association between cell line sensitivities to BI-847325 in vitro and their oncogenic alterations in the RAS/RAF/MAPK pathway. Top: Waterfall plot of BI-847325 Abs IC70 values (y-axis) per cell line (x-axis)…
View article: FIGURE 1 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
FIGURE 1 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
In vitro antiproliferative activity of BI-847325 tested in 294 cancer CLs. A, BI-847325 Chemical structure. B, individual dose–response curves of BI-847325 in 294 solid tumor and hematologic cancer CLs after 4 days of …
View article: Supplementary Figure S3 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
Supplementary Figure S3 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Supplementary Figure S3 shows the relative body weights of the mice treated with BI-847325 or capecitabine as monotherapy and in combination (second in vivo experiment).
View article: FIGURE 2 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
FIGURE 2 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Comparison between the in vitro antiproliferative activities of BI-847325 and the MEK inhibitor GDC-0623. A, Contingency table with counts of CLs per class of sensitivity to BI-847325 and GDC-0623 (cutoff for Abs IC70
View article: Supplementary Figure S3 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
Supplementary Figure S3 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Supplementary Figure S3 shows the relative body weights of the mice treated with BI-847325 or capecitabine as monotherapy and in combination (second in vivo experiment).
View article: Supplementary Tables 1-5 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
Supplementary Tables 1-5 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Five supplementary tables 1 to 5 giving more information about:- the culture conditions and molecular profile of the 294 cell lines tested.- the IC70 range per cancer type.- the number of "sensitive" and "less sensitive to resistant" cell …
View article: Supplementary Tables 1-5 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
Supplementary Tables 1-5 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Five supplementary tables 1 to 5 giving more information about:- the culture conditions and molecular profile of the 294 cell lines tested.- the IC70 range per cancer type.- the number of "sensitive" and "less sensitive to resistant" cell …
View article: Supplementary Figure S1 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
Supplementary Figure S1 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Supplementary Figure S1 shows a scatter plot of the GDC-0623 IC70 values across cell lines sorted by cancer entities.
View article: Supplementary Figure S1 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
Supplementary Figure S1 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Supplementary Figure S1 shows a scatter plot of the GDC-0623 IC70 values across cell lines sorted by cancer entities.
View article: Data from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
Data from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
BI-847325 is an ATP-competitive inhibitor of MEK/Aurora kinases with the potential to treat a wide range of cancers. In a panel of 294 human tumor cell lines in vitro, BI-847325 was found to be a highly selective inhibitor that was …
View article: FIGURE 1 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
FIGURE 1 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
In vitro antiproliferative activity of BI-847325 tested in 294 cancer CLs. A, BI-847325 Chemical structure. B, individual dose–response curves of BI-847325 in 294 solid tumor and hematologic cancer CLs after 4 days of …
View article: FIGURE 2 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
FIGURE 2 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Comparison between the in vitro antiproliferative activities of BI-847325 and the MEK inhibitor GDC-0623. A, Contingency table with counts of CLs per class of sensitivity to BI-847325 and GDC-0623 (cutoff for Abs IC70
View article: FIGURE 5 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
FIGURE 5 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
In vivo antitumor growth efficacy of BI-847325 in combination with capecitabine. Combinations (simultaneously or sequentially) were compared with both monotherapies. A, Tumor growth curves are represented as the relative tumo…
View article: High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
BI-847325 is an ATP-competitive inhibitor of MEK/Aurora kinases with the potential to treat a wide range of cancers. In a panel of 294 human tumor cell lines in vitro, BI-847325 was found to be a highly selective inhibitor that was active …
View article: Molecular Modes of Action of an Aqueous Nerium oleander Extract in Cancer Cells In Vitro and In Vivo
Molecular Modes of Action of an Aqueous Nerium oleander Extract in Cancer Cells In Vitro and In Vivo Open
Cancer drug resistance remains a major obstacle in clinical oncology. As most anticancer drugs are of natural origin, we investigated the anticancer potential of a standardized cold-water leaf extract from Nerium oleander L., termed Breast…
View article: Elevated MACC1 Expression in Colorectal Cancer Is Driven by Chromosomal Instability and Is Associated with Molecular Subtype and Worse Patient Survival
Elevated MACC1 Expression in Colorectal Cancer Is Driven by Chromosomal Instability and Is Associated with Molecular Subtype and Worse Patient Survival Open
Metastasis-Associated in Colon Cancer 1 (MACC1) is a strong prognostic biomarker inducing proliferation, migration, invasiveness, and metastasis of cancer cells. The context of MACC1 dysregulation in cancers is, however, still poorly under…
View article: Pharmacogenomics characterization of the MDM2 inhibitor MI-773 reveals candidate tumours and predictive biomarkers
Pharmacogenomics characterization of the MDM2 inhibitor MI-773 reveals candidate tumours and predictive biomarkers Open
View article: Author Correction: Evaluation of molecular subtypes and clonal selection during establishment of patient-derived tumor xenografts from gastric adenocarcinoma
Author Correction: Evaluation of molecular subtypes and clonal selection during establishment of patient-derived tumor xenografts from gastric adenocarcinoma Open
An amendment to this paper has been published and can be accessed via a link at the top of the paper.